The higher levels of plasma ADA activity in the present patients were well tolerated and were not associated with adverse reactions, including hemolytic anemia, thrombocytopenia or lymphoproliferation (as was reported in post-marketing experiences with ADAGEN, and may represent intrinsic complications of ADA-SCID and not ERT). This evidence concerns the gene ADA and Thrombocytopenia.